Literature DB >> 21810432

No-reflow disrupts the expression and distribution of connexin 43 in a swine model.

Yu-tong Cheng1, Yue-jin Yang, Hai-tao Zhang, Xiang-dong Li, Sheng Kang, Hai-yan Qian, Jing-lin Zhao.   

Abstract

INTRODUCTION AND
OBJECTIVES: Ischemia and ischemia/reperfusion can dephosphorylate and redistribute connexin 43 (Cx43). But it is unknown whether no-reflow phenomenon has an effect on the expression and distribution of Cx43 after acute infarction and reperfusion.
METHODS: 21 open-chest pigs were divided into three groups. Left anterior descending artery (LAD) occlusion for 90 min before 180 min of reperfusion was made in ischemia/reperfusion group. The pigs in ischemia groups were either subjected to LAD ligation for 90 min or for 270 min. No-reflow and risk regions were determined pathologically by dye staining. Cx43 expression was measured by western blotting and quantitative RT-PCR analysis. Cx43 spatial distribution was shown by immunofluorescence examination.
RESULTS: The content of phosphorylated and mRNA of Cx43 were higher in reflow region than in the no-reflow or sustained ischemic region. The distribution of Cx43 was also altered in no-reflow region.
CONCLUSIONS: There are some differences in synthesis, expression and distribution of myocardial Cx43 at microvascular level after ischemia/reperfusion. Cx43 is partially rephosphorylated with reperfusion only in the reflow myocardium.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21810432     DOI: 10.1016/j.mvr.2011.07.002

Source DB:  PubMed          Journal:  Microvasc Res        ISSN: 0026-2862            Impact factor:   3.514


  1 in total

1.  Development of a closed-artery catheter-based myocardial infarction in pigs using sponge and lidocaine hydrochloride infusion to prevent irreversible ventricular fibrillation.

Authors:  Rafael Dariolli; Celso K Takimura; Carlos A Campos; Pedro A Lemos; José E Krieger
Journal:  Physiol Rep       Date:  2014-08-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.